Comparison of high‐dose dual therapy with bismuth‐containing quadruple therapy in Helicobacter pylori ‐infected treatment‐naive patients: An open‐label, multicenter, randomized controlled trial

A comparative study of 14‐day dual therapy (esomeprazole and amoxicillin four times daily) and triple plus bismuth therapy for first‐line Helicobacter pylori infection eradication: A randomized trial

(2020) Zhiqiang Song et al.   HELICOBACTER

Eradication Efficacy of Modified Dual Therapy Compared with Bismuth-Containing Quadruple Therapy as a First-Line Treatment of Helicobacter pylori

(2019) Jing Yang et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

High‐dose PPI‐amoxicillin dual therapy with or without bismuth for first‐line Helicobacter pylori therapy: A randomized trial

(2019) Lou Yu et al.   HELICOBACTER

Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2017

(2019) et al.   JAMA Oncology

Consensus on eradication of Helicobacter pylori and prevention and control of gastric cancer in China (2019, Shanghai)

(2019) Yiqi Du et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

Correction: ACG Clinical Guideline: Treatment of Helicobacter pylori Infection

(2018) William D. Chey et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Fifth Chinese National Consensus Report on the management of Helicobacter pylori infection

(2018) Wen Zhong Liu et al.   HELICOBACTER

Helicobacter pylori management in ASEAN: The Bangkok consensus report

(2017) Varocha Mahachai et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

Association Between Helicobacter pylori Eradication and Gastric Cancer Incidence: A Systematic Review and Meta-analysis

(2016) Yi-Chia Lee et al.   GASTROENTEROLOGY

The Toronto Consensus for the Treatment of Helicobacter pylori Infection in Adults

(2016) Carlo A. Fallone et al.   GASTROENTEROLOGY

Management ofHelicobacter pyloriinfection—the Maastricht V/Florence Consensus Report

(2016) P Malfertheiner et al.   GUT

Gastric cancer

(2016) Eric Van Cutsem et al.   LANCET

High-dose Dual Therapy Is Superior to Standard First-line or Rescue Therapy for Helicobacter pylori Infection

(2015) Jyh-Chin Yang et al.   Clinical Gastroenterology and Hepatology

Potent Gastric Acid Inhibition Over 24 Hours by 4-Times Daily Dosing of Esomeprazole 20 mg

(2015) Shu Sahara et al.   DIGESTION

Helicobacter pylori Update: Gastric Cancer, Reliable Therapy, and Possible Benefits

(2015) David Y. Graham   GASTROENTEROLOGY

How to Effectively Use Bismuth Quadruple Therapy

(2015) David Y. Graham et al.   GASTROENTEROLOGY CLINICS OF NORTH AMERICA

A Comparative Study of Sequential Therapy and Standard Triple Therapy for Helicobacter pylori Infection: A Randomized Multicenter Trial

(2014) Liya Zhou et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

RE: Effects of Helicobacter pylori Treatment on Gastric Cancer Incidence and Mortality in Subgroups

(2014) D. Y. Graham et al.   JNCI-Journal of the National Cancer Institute

Effect of dosing schemes of amoxicillin on eradication rates ofHelicobacter pyloriwith amoxicillin-based triple therapy

(2013) Takahisa Furuta et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Management ofHelicobacter pyloriinfection—the Maastricht IV/ Florence Consensus Report

(2012) Peter Malfertheiner et al.   GUT

Fifteen-Year Effects of Helicobacter pylori, Garlic, and Vitamin Treatments on Gastric Cancer Incidence and Mortality

(2012) Jun-Ling Ma et al.   JNCI-Journal of the National Cancer Institute

Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial

(2011) Peter Malfertheiner et al.   LANCET

Comparison of the efficacy of triple versus quadruple therapy on the eradication of Helicobacter pylori and antibiotic resistance

(2010) Qing ZHENG et al.   Journal of Digestive Diseases

Optimal dose regimens of esomeprazole for gastric acid suppression with minimal influence of the CYP2C19 polymorphism

(2008) Horng-Yuan Lou et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial

(2008) Kazutoshi Fukase et al.   LANCET